Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling
Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
上一页
1
下一页

我们致力于开发针对肿瘤耐药和转移的创新疗法
快速链接
联系我们
电话: 025-58251030
邮箱: office@inxmed.com
公司地址: 南京市江北新区探秘路73号树屋十六栋D-2栋3层
在线留言
关注我们:
CopyRight © 2022 应世生物 All Rights Reserved.